drug

KYN-5356

as of 2026-07-01
Add to landscapeMonitor thisCompare thisAsk about this
at a glance
small molecule
Pre-approval / investigational in the US
Developed by Kynexis B.V.
1 trials in the graph
Synthesized from structured facts only — each point cited above.

Mechanism & identity

Modality
small molecule

Indications

Trials

1
A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of KYN-5356 in Healthy Subjects Aged 18 to 55 Years
NCT06225115Phase 1Completed

KOLs & investigators

1
Hakop Gevorkyan, MD, MBA

Facts & assertions

0 sourced
No assertions recorded for this entity.
relationships
The graph out of here
developer
Kynexis B.V.
company
trial
A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of KYN-5356 in Healthy Subjects Aged 18 to 55 Years
PHASE1
trial
indication
Schizophrenia
indication
Schizophrenia
indication
Cognitive Dysfunction
indication
Cognitive Dysfunction
indication
KOL
Hakop Gevorkyan, MD, MBA
KOL score —
person